Search

Displaying results 4021 - 4030 of 10000 in total
  1. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.

    Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
  2. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

  3. Drug

    Cynodon dactylon pollen

    go.drugbank.com/drugs/DB10351
    Approved

    It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

  4. Drug

    Ethyl macadamiate

    go.drugbank.com/drugs/DB11243
    Approved

    Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.

  5. Drug

    Viper antivenom

    go.drugbank.com/drugs/DB14114
    ApprovedInvestigational

    ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

  6. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  7. Drug

    Iolopride I-123

    go.drugbank.com/drugs/DB20028
    Experimental

    The usage of the INN stem '-pride' in the name indicates that Iolopride I-123 is a sulpiride derivative and analogue. Iolopride I-123 has a monoisotopic molecular weight of 400.06 Da.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  9. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

  10. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.